Fabrazyme (agalsidase beta) + Placebo

ApprovedCompleted
0 views this week 0 watching Active
Interest: 43/100
43
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Fabry Disease

Conditions

Fabry Disease

Trial Timeline

Feb 1, 2001 → Jan 1, 2004

About Fabrazyme (agalsidase beta) + Placebo

Fabrazyme (agalsidase beta) + Placebo is a approved stage product being developed by Sanofi for Fabry Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00074984. Target conditions include Fabry Disease.

What happened to similar drugs?

8 of 20 similar drugs in Fabry Disease were approved

Approved (8) Terminated (4) Active (11)

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00074984ApprovedCompleted